NCT03726866

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

A Randomized, Open Label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions and Safety Among D326, D337 and CKD-828 in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 40 Years
• Healthy volunteers: Accepted

Summary

To evaluate pharmacokinetic properties and drug interactions between D326 and D337 co-administered groups, the CKD-828 alone and the total co-administered groups.

Conditions

• Dyslipidemias
• Hypertension

Interventions

Type	Name	Description
DRUG	Sequence 1	D326, D337 or CKD-828 for 9 days
DRUG	Sequence 2	D326, D337 or CKD-828 for 9 days
DRUG	Sequence 3	D326, D337 or CKD-828 for 9 days
DRUG	Sequence 4	D326, D337 or CKD-828 for 9 days
DRUG	Sequence 5	D326, D337 or CKD-828 for 9 days
DRUG	Sequence 6	D326, D337 or CKD-828 for 9 days

Timeline

• Start date: 2018-08-31
• Primary completion: 2019-01-15
• Completion: 2019-01-15
• First posted: 2018-11-01
• Last updated: 2018-11-01

Locations

1 site across 1 country: South Korea